Cordis starts trial of new AAA stent
This article was originally published in Clinica
A new stent called Incraft is being developed by Cordis as a treatment for abdominal aortic aneurysm (AAA). The Johnson & Johnson subsidiary has started an open-label, non-randomised trial called INNOVATION, which will enrol 25 AAA patients. The stent can be customised to the individual patient during the implantation procedure, and has an "ultra-low-profile delivery system". Incraft's delivery system profile is 13 French, whereas most endovascular aneurysm repair (EVAR) devices have a profile ranging from 18 to 24 French. This should broaden the patient population who can be treated with stents; many AAA patients, especially women, cannot undergo EVAR because current stents are too large to be placed in small or diseased access vessels. An estimated 27 million people worldwide have AAAs. Left untreated, all aneurysms will eventually rupture, and ruptured aneurysms are fatal in more than 80% of cases.
You may also be interested in...
Dr Noam Emanuel is the founder and chief technology officer of Ness Ziona, Israel-based drug delivery firm PolyPid. The 15-strong firm, established in 2008, has developed an encapsulation technology which allows the precise targeting of drug release.
Mesoblast has received the all-clear from the US FDA to start a Phase III clinical trial for bone marrow regeneration in patients with blood cancers. The study will be conducted together with Mesoblast's strategic alliance partner, Cephalon, which will fund the trial.
Mesoblast has received the green light from the US FDA to begin a Phase II trial of its proprietary adult mesenchymal precursor cell (MPC) product for the treatment of degenerative disc disease, a major cause of chronic low back pain.